Latest news on when mirikizumab will be launched in China

As of now (End of January 2026), Mirikizumab (Mirikizumab) original research drug has not yet been officially launched in China. The common specifications in overseas markets are 300mg/15mL each, used for intravenous infusion or subcutaneous injection. The drug is mainly approved in Europe, the United States and some Asian countries, and is used to treat patients with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD). Since China has not yet approved its marketing, patients in China cannot directly obtain the original drug through medical insurance channels or regular pharmacies.

1. Market dynamics and potential time to market

According to overseas registration and pharmaceutical company announcements, the registration and approval of militizumab in China is still in progress. Pharmaceutical companies are required to submit clinical trial data, drug safety and effectiveness reports, and undergo review by the national drug regulatory authorities (such asNMPA). Affected by the approval process, clinical data supplementation and policy adjustments, the specific launch time is still uncertain, but the industry generally expects that the original drug will apply for launch in the next few years.

2. Patient acquisition and focus

1) Pay attention to clinical trials: Patients can obtain treatment opportunities in advance by participating in ongoing domestic clinical trials of Milizumab, and at the same time understand the efficacy and safety of the drug on different groups of people.

2) Pay attention to official announcements: Drug listing information is subject to NMPA announcements or pharmaceutical company news. Do not trust "advance purchase" information from unofficial channels.

3) Risk warning for purchasing drugs overseas: In overseas markets, if patients purchase drugs by themselves, they need to confirm that the source of the drugs is formal and pay attention to storage conditions and temperature management during transportation.

3. Clinical significance

The launch of militizumab in China will provide new treatment options for patients with moderate to severe inflammatory bowel disease, especially those who have poor response or low tolerance to traditional drugs. Through scientific management and correct medication, patients can achieve better symptom control and improved quality of life.

Keyword tags: Mirikizumab launched in China,Mirikizumab launched, inflammatory bowel disease treatment, ulcerative colitis, Crohn's disease, clinical trials, drug approval trends, drug safety

References:https://omvoh.lilly.com/